Theravance Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Theravance Biopharma

23/02/2022 23:35

* Theravance Biopharma Inc  TBPH.OQ  reported a quarterly
adjusted
loss of 43 cents​​ per share for the quarter ended in December.
The mean expectation of eight analysts for the quarter was for a
loss of 33 cents per share.
    * Revenue fell 20.2% to $14.95 million from a year ago; 
analysts
expected $13.48 million. 
    * Theravance Biopharma Inc's reported EPS for the quarter
was a
loss of 43 cents​.
    * The mean earnings estimate of analysts had risen by
about 15% in
the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Theravance Biopharma Inc shares had fallen by 15.5% this
quarter.
    * The company reported a quarterly loss of $32.04 million.
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $10.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated February 23 at 11:35 p.m.
 ​All figures in US dollars unless otherwise stated